,

The Path from Biomarker Discovery to Regulatory Qualification

Specificaties
Paperback, blz. | Engels
Elsevier Science | 2013
ISBN13: 9780123914965
Rubricering
Elsevier Science e druk, 2013 9780123914965
€ 56,14
Levertijd ongeveer 9 werkdagen
Gratis verzonden

Samenvatting

The Path from Biomarker Discovery to Regulatory Qualification is a unique guide that focuses on biomarker qualification, its history and current regulatory settings in both the US and abroad. This multi-contributed book provides a detailed look at the next step to developing biomarkers for clinical use and covers overall concepts, challenges, strategies and solutions based on the experiences of regulatory authorities and scientists. Members of the regulatory, pharmaceutical and biomarker development communities will benefit the most from using this book—it is a complete and practical guide to biomarker qualification, providing valuable insight to an ever-evolving and important area of regulatory science.

For complimentary access to chapter 13, 'Classic' Biomarkers of Liver Injury, by John R. Senior, Associate Director for Science, Food and Drug Administration, Silver Spring, Maryland, USA, please visit the following site: http://tinyurl.com/ClassicBiomarkers

Specificaties

ISBN13:9780123914965
Taal:Engels
Bindwijze:Paperback

Inhoudsopgave

<p>1. Biomarker Applications in the Pharmaceutical Industry<br>2. The Impact of Biomarker Qualification Regulatory Processes on the Critical Path for Drug Development<br>3. Regulatory Experience at the EMA<br>4. Regulatory Experience at the PMDA</p> <p>Section 1: Biomarker Development and Qualification in the Pharmaceutical Industry<br>5. Pfizer<br>6. Astra Zeneca<br>7. Novartis<br>8. BMS<br>9. CTCs</p> <p>Section 2: Toxicogenomic Biomarkers <br>10. Gene Logic<br>11. Johnson and Johnson<br>12. ILSI-HESI</p> <p>Section 3: Biomarkers of Drug Safety<br>13. “Classic” Markers of Liver Injury<br>14. Urinary Biomarkers of Kidney Injury</p> <p>Section 4: Consortia<br>15. ILSI-HESI<br>16. C-Path Institute<br>17. Beyond QT</p> <p>Section 5: Path to Regulatory Qualification Process Development<br>18. FDA<br>19. PMDA<br>20. The tortuous path from development to qualification of biomarkers</p>
€ 56,14
Levertijd ongeveer 9 werkdagen
Gratis verzonden

Rubrieken

    Personen

      Trefwoorden

        The Path from Biomarker Discovery to Regulatory Qualification